Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

Company Overview

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Key Stats

• Today's Range: $8.41 to $8.80
• 50-Day Range: $8.21 to $11.24
• 52-Week Range: $8.06 to $27.71
• Volume: 97,870 shs
• Average Volume: 1.00 million shs
• Market Capitalization: $901.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.00
• Consensus Rating: Moderate Buy

Rocket Pharmaceuticals Stock Analysis - MarketRank™

Rocket Pharmaceuticals scored higher than 95% of companies evaluated by MarketBeat, and ranked 37th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rocket Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Rocket Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.83) to ($2.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rocket Pharmaceuticals is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rocket Pharmaceuticals is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rocket Pharmaceuticals has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.94% of the float of Rocket Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Rocket Pharmaceuticals has recently decreased by 1.78%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rocket Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rocket Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.81

Percentage of Shares Shorted

16.94% of the float of Rocket Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Rocket Pharmaceuticals has recently decreased by 1.78%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.15

News Sentiment

Rocket Pharmaceuticals has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Rocket Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 8 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

5 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,300.00 in company stock.

Percentage Held by Insiders

28.50% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RCKT Stock Analysis - Frequently Asked Questions

How have RCKT shares performed this year?

Rocket Pharmaceuticals' stock was trading at $12.57 at the beginning of the year. Since then, RCKT stock has decreased by 30.5% and is now trading at $8.73.
View the best growth stocks for 2025 here.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) posted its earnings results on Monday, March, 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.06.

Who are Rocket Pharmaceuticals' major shareholders?

Top institutional shareholders of Rocket Pharmaceuticals include Wellington Management Group LLP (13.12%), Vanguard Group Inc. (7.22%), Janus Henderson Group PLC (4.39%) and Price T Rowe Associates Inc. MD (3.45%). Insiders that own company stock include Rtw Investments, Lp, Gaurav Shah, Gotham Makker, Kinnari Patel, Jonathan David Schwartz, Mark Andrew White, Martin Wilson and John Militello.
View institutional ownership trends.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Marinus Pharmaceuticals (MRNS), Waste Connections (WCN), Humana (HUM), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 3/03/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RCKT
• CIK: 1281895
• Web: www.rocketpharma.com
• Phone: (609) 659-8001
• Fax: 646-224-9585
• Employees: 240
• Year Founded: 2018

Price Target and Rating

• Average Stock Price Target: $43.00
• High Stock Price Target: $65.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +392.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-245,600,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.62%
• Return on Assets: -54.17%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 6.05
• Quick Ratio: 6.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.46 per share
• Price / Book: 1.60

Miscellaneous

• Outstanding Shares: 106,630,000
• Free Float: 65,177,000
• Market Cap: $930.88 million
• Optionable: Optionable
• Beta: 1.03